Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TPST files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Departure Of Cfo (new) — The Principal Financial Officer resigned from all positions with no disclosed reason.
Tempest Therapeutics CFO Justin Trojanowski resigns; Nicholas Rossettos appointed
Filed August 24, 2026 · Period ending August 18, 2026 · ~1 min read
Key Changes
-
high
CFO Justin Trojanowski resigned from all positions effective Sept 1, 2026. Filing does not disclose reason or whether departure was voluntary.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR → -
high
Nicholas Rossettos, 60, appointed CFO effective Sept 1 with no gap. Brings 30+ years finance experience including interim CFO at Sernova Corp and fractional CFO work with emerging biotech companies.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR →
Summary
Tempest Therapeutics disclosed the resignation of CFO Justin Trojanowski effective September 1, 2026. The filing provides no explanation for the departure or whether it was voluntary, which raises questions about the circumstances. The company immediately appointed Nicholas Rossettos to fill the role with no gap in financial leadership.
Rossettos brings relevant experience from the biotechnology sector, having recently served as interim CFO at clinical-stage company Sernova Corp and as a financial advisor to TransCode Therapeutics. Since 2012, he has specialized in providing fractional CFO services to emerging and growth-stage businesses. While the immediate replacement provides operational continuity, the unexplained nature of Trojanowski's departure warrants attention from investors, particularly given the critical role of financial leadership in a clinical-stage company.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Effective September 1, 2026, the Board of Directors of the Company (the “Board”) appointed Mr. Nicholas Rossettos as Chief Financial Officer Principal Financial and Accounting Officer, Treasurer, and Corporate Secretary of the Company.
Nicholas Rossettos was appointed as Chief Financial Officer, Principal Financial and Accounting Officer, Treasurer, and Corporate Secretary effective September 1, 2026. The appointment ensures continuity in the financial leadership role with no gap between the outgoing and incoming CFO.
Added in current filing · verify on EDGAR →
Prior to joining the Company, Mr. Rossettos, 60, served as a financial advisor to TransCode Therapeutics, Inc. (Nasdaq: RNAZ) since April 2025 and as Interim Chief Financial Officer of Sernova Corp. (TSX: SVA), a clinical-stage biotechnology company, from March 2024 to October 2024. Since 2012, Mr. Rossettos has provided consulting chief financial officer services to emerging and growth-stage businesses, including as fractional chief financial officer with Charles River CFO.
Rossettos brings relevant biotechnology sector experience, having recently served as interim CFO at Sernova Corp and as a financial advisor to TransCode Therapeutics. Since 2012, he has specialized in providing fractional CFO services to emerging companies, indicating expertise in early-stage and growth-stage business environments similar to Tempest's profile.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 24, 2026 · How we verify